1
|
Tapia-Rivera JC, Mendoza-Jaramillo HE, González-Villaseñor CO, Ramirez-Flores M, Aguilar-Velazquez JA, López-Quintero A, Pérez-Guerrero EE, Vargas-Rodriguez MDLÁ, Gutiérrez-Hurtado IA, Martínez-López E. Effect of Human Adenovirus 36 on Response to Metformin Monotherapy in Obese Mexican Patients with Type 2 Diabetes: A Prospective Cohort Study. Viruses 2023; 15:1514. [PMID: 37515200 PMCID: PMC10386570 DOI: 10.3390/v15071514] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 07/04/2023] [Accepted: 07/05/2023] [Indexed: 07/30/2023] Open
Abstract
Human adenovirus 36 (HAdV-36) has been associated with obesity and changes in glucose and lipid metabolism. The virus has been reported to increase insulin sensitivity and paradoxically promote weight gain. Because of its effects on metabolism, infection with the virus could alter the response to several drugs used to treat type 2 diabetes (DM2), such as metformin. The aim of this study was to test whether HAdV-36 affects the response to metformin in a group of obese patients with DM2. METHODS In a prospective cohort study, 103 obese patients with newly diagnosed DM2 were divided into two groups based on their HAdV-36 seropositivity (+HAdV-36 and -HAdV-36). Weight, glucose, cholesterol, triglycerides, body mass index, body fat percentage, and waist and hip circumference were measured and compared in both groups at baseline and after 45 days of metformin treatment. RESULTS Only glucose was significantly lower in the +HAdV-36 group at baseline, while all other variables were similar between the two study groups. After 45 days of follow-up, it was observed that the effect of metformin did not differ between the groups, but the variables improved significantly after treatment. CONCLUSIONS In this study, we did not find that HAdV-36 had an effect on the response to metformin in obese patients with DM2.
Collapse
Affiliation(s)
- José Carlos Tapia-Rivera
- Departamento de Ciencias Básicas para la Salud, Centro Universitario del Sur, Universidad de Guadalajara, Ciudad Guzmán 49000, Mexico
| | - Héctor Eduardo Mendoza-Jaramillo
- Departamento de Ciencias Básicas para la Salud, Centro Universitario del Sur, Universidad de Guadalajara, Ciudad Guzmán 49000, Mexico
| | | | - Mario Ramirez-Flores
- Centro de Investigaciones Biomédicas, Universidad de Colima, Colima 28040, Mexico
| | - José Alonso Aguilar-Velazquez
- Departamento de Morfología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
| | - Andres López-Quintero
- Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
| | - Edsaúl Emilio Pérez-Guerrero
- Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
| | - María de Los Ángeles Vargas-Rodriguez
- Doctorado en Ciencias de la Nutrición Traslacional, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
| | - Itzae Adonai Gutiérrez-Hurtado
- Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
| | - Erika Martínez-López
- Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
- Instituto de Nutrigenética y Nutrigenómica Traslacional, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico
| |
Collapse
|
2
|
Delgado-Enciso I, Paz-Garcia J, Barajas-Saucedo CE, Mokay-Ramírez KA, Meza-Robles C, Lopez-Flores R, Delgado-Machuca M, Murillo-Zamora E, Toscano-Velazquez JA, Delgado-Enciso J, Melnikov V, Walle-Guillen M, Galvan-Salazar HR, Delgado-Enciso OG, Cabrera-Licona A, Danielewicz-Mata EJ, Mandujano-Diaz PJ, Guzman-Esquivel J, Montes-Galindo DA, Perez-Martinez H, Jimenez-Villegaz JM, Hernandez-Rangel AE, Montes-Diaz P, Rodriguez-Sanchez IP, Martinez-Fierro ML, Garza-Veloz I, Tiburcio-Jimenez D, Zaizar-Fregoso SA, Gonzalez-Alcaraz F, Gutierrez-Gutierrez L, Diaz-Lopez L, Ramirez-Flores M, Guzman-Solorzano HP, Gaytan-Sandoval G, Martinez-Perez CR, Espinoza-Gómez F, Rojas-Larios F, Hirsch-Meillon MJ, Baltazar-Rodriguez LM, Barrios-Navarro E, Oviedo-Rodriguez V, Mendoza-Hernandez MA, Prieto-Diaz-Chavez E, Paz-Michel BA. Safety and efficacy of a COVID-19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs. usual medical care alone: A randomized, open-label, controlled trial. Exp Ther Med 2021; 22:915. [PMID: 34306189 PMCID: PMC8281484 DOI: 10.3892/etm.2021.10347] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Accepted: 05/11/2021] [Indexed: 12/13/2022] Open
Abstract
Coronavirus disease 2019 (COVID-19) is currently the major public health problem worldwide. Neutral electrolyzed saline solution that contains reactive chlorine and oxygen species may be an effective therapeutic. In the present study, the treatment efficacy of intravenous and/or nebulized neutral electrolyzed saline combined with usual medical care vs. usual medical care alone was evaluated in ambulatory patients with COVID-19. A prospective, 2-arm, parallel-group, randomized, open-label, multi-center, phase I-II clinical trial including 214 patients was performed. The following two outcomes were evaluated during the 20-day follow-up: i) The number of patients with disease progression; and ii) the patient acceptable symptom state. Serial severe acute respiratory syndrome coronavirus 2 naso/oro-pharyngeal detection by reverse transcription-quantitative (RT-q) PCR was performed in certain patients of the experimental group. Biochemical and hematologic parameters, as well as adverse effects, were also evaluated in the experimental group. The experimental treatment decreased the risk of hospitalization by 89% [adjusted relative risk (RR)=0.11, 95% confidence interval (CI): 0.03-0.37, P<0.001] and the risk of death by 96% (adjusted RR=0.04, 95% CI: 0.01-0.42, P=0.007) and also resulted in an 18-fold higher probability of achieving an acceptable symptom state on day 5 (adjusted RR=18.14, 95% CI: 7.29-45.09, P<0.001), compared with usual medical care alone. Overall, neutral electrolyzed saline solution was better than usual medical care alone. Of the patients analyzed, >50% were negative for the virus as detected by RT-qPCR in naso/oro-pharyngeal samples on day 4, with only a small number of positive patients on day 6. Clinical improvement correlated with a decrease in C-reactive protein, aberrant monocytes and increased lymphocytes and platelets. Cortisol and testosterone levels were also evaluated and a decrease in cortisol levels and an increase in the testosterone-cortisol ratio were observed on days 2 and 4. The experimental treatment produced no serious adverse effects. In conclusion, neutral electrolyzed saline solution markedly reduced the symptomatology and risk of progression in ambulatory patients with COVID-19. The present clinical trial was registered in the Cuban public registry of clinical trials (RPCEC) database (May 5, 2020; no. TX-COVID19: RPCEC00000309).
Collapse
Affiliation(s)
- Ivan Delgado-Enciso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Juan Paz-Garcia
- Department of Internal Medicine and Surgery, Union Hospital Center, Villa de Álvarez, Colima 28970, México
| | - Carlos E Barajas-Saucedo
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Karen A Mokay-Ramírez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Carmen Meza-Robles
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Rodrigo Lopez-Flores
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Marina Delgado-Machuca
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Efren Murillo-Zamora
- Department of Research, General Hospital of Zone No. 1 and Family Medicine Unit No. 19 IMSS, Villa de Alvarez, Colima 28984, México
| | - Jose A Toscano-Velazquez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Josuel Delgado-Enciso
- Department of Research, Foundation for Cancer Ethics, Education and Research of the Cancerology State Institute, Colima 28085, México
| | - Valery Melnikov
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Mireya Walle-Guillen
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Hector R Galvan-Salazar
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Osiris G Delgado-Enciso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Foundation for Cancer Ethics, Education and Research of the Cancerology State Institute, Colima 28085, México
| | | | | | - Pablo J Mandujano-Diaz
- COVID-19 Respiratory Care Clinic INSABI Poliforum, Tuxtla Gutierrez, Chiapas 29040, México
| | - José Guzman-Esquivel
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Foundation for Cancer Ethics, Education and Research of the Cancerology State Institute, Colima 28085, México
| | - Daniel A Montes-Galindo
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Henry Perez-Martinez
- COVID-19 Respiratory Care Clinic INSABI Poliforum, Tuxtla Gutierrez, Chiapas 29040, México
| | | | | | | | - Iram P Rodriguez-Sanchez
- Laboratory of Molecular and Structural Physiology, School of Biological Sciences, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo León 66455, México
| | - Margarita L Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, México
| | - Idalia Garza-Veloz
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, México
| | - Daniel Tiburcio-Jimenez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Sergio A Zaizar-Fregoso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | | | | | - Luciano Diaz-Lopez
- COVID-19 Respiratory Care Clinic INSABI Poliforum, Tuxtla Gutierrez, Chiapas 29040, México
| | - Mario Ramirez-Flores
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | | | - Gustavo Gaytan-Sandoval
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Carlos R Martinez-Perez
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Francisco Espinoza-Gómez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Fabián Rojas-Larios
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Michael J Hirsch-Meillon
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | - Luz M Baltazar-Rodriguez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Enrique Barrios-Navarro
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México
| | - Vladimir Oviedo-Rodriguez
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, México
| | | | | | - Brenda A Paz-Michel
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, México.,Department of Research, Esteripharma S.A. de C.V., Ciudad de México 03100, México
| |
Collapse
|
3
|
Lara-Esqueda A, Zaizar-Fregoso SA, Madrigal-Perez VM, Ramirez-Flores M, Montes-Galindo DA, Martinez-Fierro ML, Rodriguez-Sanchez IP, Guzman-Esquivel J, Meza-Robles C, Ceja-Espiritu G, Kuri-Morales PA, Delgado-Enciso J, Barriguete-Melendez A, Galvan-Salazar HR, Barajas-Saucedo CE, Guillermo-Espinosa E, Lara-Basulto AD, Gonzalez-Roldan JF, Delgado-Enciso I. Evaluation of Medical Care for Diabetic and Hypertensive Patients in Primary Care in Mexico: Observational Retrospective Study. J Diabetes Res 2021; 2021:7365075. [PMID: 34426789 PMCID: PMC8380161 DOI: 10.1155/2021/7365075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/26/2021] [Accepted: 07/22/2021] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION The present study evaluated the quality of medical care for patients diagnosed with diabetes mellitus (DM), hypertension (HBP), and both pathologies (DM+HBP) within a public health system in Mexico. METHODS 45,498 patients were included from 2012 to 2015. All information was taken from the electronic medical record database. Each patient record was compared against the standard to test the quality of medical care. RESULTS Glycemia with hypertension goals reached 29.6% in DM+HBP, 48.6% in DM, and 53.2% in HBP. The goals of serum lipids were reached by 3% in DM+HBP, 5% in DM, and 0.2% in HBP. Glycemia, hypertension, and LDL cholesterol reached 0.04%. 15% of patients had an undiagnosed disease. Clinical follow-up examinations reached 20% for foot examination and clinical eye examination. Specialty referrals reached 1% in angiology or cardiology. CONCLUSION Goals for glycemic and hypertension reached 50% in the overall population, while serum lipids, clinical follow-up examinations, and referral to a specialist were deficient. Patients who had both diseases had more consultations, better control for hypertension and lipids, but inferior glycemic control. Overall, quality care for DM and/or HBP has not been met according to the standards.
Collapse
Affiliation(s)
- Agustin Lara-Esqueda
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Sergio A. Zaizar-Fregoso
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Violeta M. Madrigal-Perez
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Mario Ramirez-Flores
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | - Daniel A. Montes-Galindo
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Margarita L. Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Zacatecas Autonomous University, Zacatecas 98160, Mexico
| | - Iram P. Rodriguez-Sanchez
- Molecular and Structural Physiology Laboratory, School of Biological Sciences, Autonomous University of Nuevo León, Monterrey, Nuevo León 64460, Mexico
| | - José Guzman-Esquivel
- Department of Research, Mexican Social Security Institute, Villa de Alvarez, Colima 28983, Mexico
| | - Carmen Meza-Robles
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Gabriel Ceja-Espiritu
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| | - Pablo A. Kuri-Morales
- School of Medicine, Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, 04510, Mexico
| | - Josuel Delgado-Enciso
- Fundación para la Etica, Education e Investigación del Cáncer del Instituto Estatal de Cancerologia de Colima, Colima 28085, Mexico
| | | | - Hector R. Galvan-Salazar
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | | | | | - Agustin D. Lara-Basulto
- Department of Research, Cancerology State Institute, Colima State Health Services, Colima 28085, Mexico
| | - Jesus F. Gonzalez-Roldan
- Subsecretaria de Prevención y Promoción de la Salud, Secretaria de Salud de Mexico, Ciudad de Mexico, 06600, Mexico
| | - Ivan Delgado-Enciso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico
| |
Collapse
|
4
|
Delgado-Enciso I, Paz-Garcia J, Barajas-Saucedo CE, Mokay-Ramírez KA, Meza-Robles C, Lopez-Flores R, Delgado-Machuca M, Murillo-Zamora E, Toscano-Velazquez JA, Delgado-Enciso J, Melnikov V, Walle-Guillen M, Galvan-Salazar HR, Delgado-Enciso OG, Cabrera-Licona A, Guzman-Esqu J, Montes-Galindo DA, Hernandez-Rangel AE, Montes-Diaz P, Rodriguez-Sanchez IP, Martinez-Fierro ML, Garza-Veloz I, Tiburcio-Jimenez D, Zaizar-Fregoso SA, Ramirez-Flores M, Gaytan-Sandoval G, Martinez-Perez CR, Espinoza-Gómez F, Rojas-Larios F, Hirsch-Meillon MJ, Barrios-Navarro E, Oviedo-Rodriguez V, Rodriguez LMB, Paz-Michel BA. Patient-Reported Health Outcomes After Treatment of COVID-19 with Nebulized and/or Intravenous Neutral Electrolyzed Saline Combined with Usual Medical Care Versus Usual Medical care alone: A Randomized, Open-Label, Controlled Trial. Res Sq 2020. [PMID: 32935090 PMCID: PMC7491578 DOI: 10.21203/rs.3.rs-68403/v1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Background: Coronavirus disease (COVID-19) is currently the main public health problem worldwide. The administration of neutral electrolyzed saline, a solution that contains reactive species of chlorine and oxygen (ROS), may be an effective therapeutic alternative due to its immunomodulating characteristics, in systemic inflammation control, as well as in immune response improvement, promoting control of the viral infection. The present study evaluated the efficacy of treatment with intravenous and/or nebulized neutral electrolyzed saline combined with usual medical care versus usual medical care alone, in ambulatory patients with COVID-19. Methods: A prospective, 2-arm, parallel group, randomized, open-label, phase I-II clinical trial included 39 patients in the control group (usual medical care alone) and 45 patients in the experimental group (usual medical care + intravenous and/or nebulized electrolyzed saline, with dose escalation). Two aspects were evaluated during the twenty-day follow-up: i) the number of patients with disease progression (hospitalization or death); and ii) the Patient Acceptable Symptom State (PASS), a single-question outcome that determines patient well-being thresholds for pain and function. Biochemical and hematologic parameters, as well as adverse effects, were evaluated in the experimental group. Results: The experimental treatment decreased the risk for hospitalization by 92% (adjusted RR=0.08, 95% CI: 0.01–0.50, P=0.007), with a 43-fold increase in the probability of achieving an acceptable symptom state on day 5 (adjusted RR= 42.96, 95% CI: 9.22–200.0, P<0.001). Intravenous + nebulized administration was better than nebulized administration alone, but nebulized administration was better than usual medical care alone. Clinical improvement correlated with a decrease in C-reactive protein, and aberrant monocytes and an increase of lymphocytes, and platelets. Cortisol and testosterone levels were also evaluated, observing a decrease in cortisol levels and an increment of testosterone-cortisol ratio, on days 2 and 4. Conclusions: The experimental treatment produced no serious adverse effects. In conclusion, intravenous and/or nebulized neutral electrolyzed saline importantly reduced the symptomatology and risk of progression (hospitalization and death), in ambulatory patients with COVID-19. Trial registration: Cuban Public Registry of Clinical Trials (RPCEC) Database RPCEC00000309. Registered: 05. May 2020. https://rpcec.sld.cu/en/trials/RPCEC00000309-En
Collapse
|
5
|
Meza-Robles C, Barajas-Saucedo CE, Tiburcio-Jimenez D, Mokay-Ramírez KA, Melnikov V, Rodriguez-Sanchez IP, Martinez-Fierro ML, Garza-Veloz I, Zaizar-Fregoso SA, Guzman-Esquivel J, Ramirez-Flores M, Newton-Sanchez OA, Espinoza-Gómez F, Delgado-Enciso OG, Centeno-Ramirez AS, Delgado-Enciso I. One-step nested RT-PCR for COVID-19 detection: A flexible, locally developed test for SARS-CoV2 nucleic acid detection. J Infect Dev Ctries 2020; 14:679-684. [PMID: 32794453 DOI: 10.3855/jidc.12726] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2020] [Accepted: 06/22/2020] [Indexed: 10/31/2022] Open
Abstract
INTRODUCTION Due to the coronavirus pandemic, identifying the infected individuals has become key to limiting its spread. Virus nucleic acid real-time RT-PCR testing has become the current standard diagnostic method but high demand could lead to shortages. Therefore, we propose a detection strategy using a one-step nested RT-PCR. METHODOLOGY The nucleotide region in the ORF1ab gene that has the greatest differences between the human coronavirus and the bat coronavirus was selected. Primers were designed after that sequence. All diagnostic primers are species-specific since the 3´ end of the sequence differs from that of other species. A primer set also creates a synthetic positive control. Amplified products were seen in a 2.5% agarose gel, as well as in an SYBR Green-Based Real-Time RT-PCR. RESULTS Amplification was achieved for the positive control and specific regions in both techniques. CONCLUSIONS This new technique is flexible and easy to implement. It does not require a real-time thermocycler and can be interpreted in agarose gels, as well as adapted to quantify the viral genome. It has the advantage that if the coronavirus mutates in one of the key amplification nucleotides, at least one pair can still amplify, thanks to the four diagnostic primers.
Collapse
Affiliation(s)
- Carmen Meza-Robles
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
| | - Carlos E Barajas-Saucedo
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
| | - Daniel Tiburcio-Jimenez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
| | - Karen A Mokay-Ramírez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
| | - Valery Melnikov
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
| | - Iram P Rodriguez-Sanchez
- Molecular and Structural Physiology Laboratory, School of Biological Sciences, Autonomous University of Nueo León, Monterrey, Nuevo León 64460, Mexico.
| | - Margarita L Martinez-Fierro
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico.
| | - Idalia Garza-Veloz
- Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico
| | - Sergio A Zaizar-Fregoso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
| | - José Guzman-Esquivel
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
| | - Mario Ramirez-Flores
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
| | - Oscar A Newton-Sanchez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
| | - Francisco Espinoza-Gómez
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
| | - Osiris G Delgado-Enciso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
| | | | - Ivan Delgado-Enciso
- Department of Molecular Medicine, School of Medicine, University of Colima, Colima 28040, Mexico.
| |
Collapse
|
6
|
Ramirez-Flores M, Delgado-Enciso I, Fernandez-Salinas ARG, Valdez-Velazquez LL, Guzman-Esquivel J, Baltazar-Rodriguez LM. HPV 16 and 18 viral loads are greater in patients with high-grade cervical epithelial lesions. EUR J GYNAECOL ONCOL 2016; 37:644-648. [PMID: 29787002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
BACKGROUND Cervical cancer is the second most common cancer in women worldwide. High-risk infection with HPV type 16 or type 18 is the most important risk factor associated with the development of cervical cancer. AIMS To determine the viral load of HPV-16 and HPV-1 8 in samples from women with cervical epithelial lesion in the State of Colima, Mexico. MATERIALS AND METHODS A cross-sectional analytic study was conducted that included 45 samples positive for HPV- 16 and 45 samples positive for HPV-1 8 from patients with cervical cancer or precursor lesion. Real time PCR was employed to determine the number of copies /101 cells. Viral load was determined in the two groups of patients and correlated with tumor grade. RESULTS THe authors found that the HPV-1 6 viral load was greater than that of HPV-18 through a Mann-Whitney U analysis, resulting in ap = 0.000; as the malignancy of the cervical lesion progressed, the viral load increased, and HPV-16 showed a moderate positive association with an r = 0.509 and a p = 0.000, whereas HPV-18 showed a weak positive correlation with an r = 0.372 and a p = 0.0 12. CONCLUSIONS The viral load of HPV-16 was greater than that of HPV-18. The HPV-16 viral load had a moderate positive association in relation to cervical lesion severity, whereas the viral load of HPV- 18 had a weak positive correlation with respect to the cervical lesion grade.
Collapse
|
7
|
Rojo-Contreras W, Olivas-Flores EM, Gamez-Nava JI, Montoya-Fuentes H, Trujillo-Hernandez B, Trujillo X, Suarez-Rincon AE, Baltazar-Rodriguez LM, Sanchez-Hernandez J, Ramirez-Flores M, Vazquez-Salcedo J, Rojo-Contreras J, Morales-Romero J, Gonzalez-Lopez L. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus 2011; 21:365-72. [DOI: 10.1177/0961203311425517] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Cervical human papillomavirus (HPV+) infection is associated with an increased risk of cervical dysplasia. Although the frequency of HPV+ in systemic lupus erythematosus (SLE) has been investigated in some races its prevalence in Hispanic women is still unknown. This cross-sectional study evaluated the prevalence of cervical HPV+ in Mexican women with SLE ( n = 34) or rheumatoid arthritis (RA) ( n = 43) and in healthy controls ( n = 146). These women were interviewed about risk factors for sexually transmitted infections and cervical cytology analysis was performed. HPV+ viral types were identified using PCR: HPV+ was observed in 14.7% of SLE, 27.9% of RA and 30.8% of controls. High-risk HPV types were observed in 11.7% of women with SLE, 27.9% of women with RA, and in 26% of the controls. High-risk viral types 58, 35 and 18 were the most frequently identified in SLE. Two women with SLE had a high-grade squamous intraepithelial lesion and one had cervical cancer. An association was observed between methotrexate utilization, longer duration of therapy with prednisone, and HPV+ in RA or SLE. Thus, there is a high prevalence of cervical HPV infection in Mexican women with SLE or RA, and physicians must be vigilant in preventing the development of cervical dysplasia.
Collapse
Affiliation(s)
- W Rojo-Contreras
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - EM Olivas-Flores
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - JI Gamez-Nava
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - H Montoya-Fuentes
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - B Trujillo-Hernandez
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - X Trujillo
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - AE Suarez-Rincon
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - LM Baltazar-Rodriguez
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - J Sanchez-Hernandez
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - M Ramirez-Flores
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - J Vazquez-Salcedo
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - J Rojo-Contreras
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - J Morales-Romero
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| | - L Gonzalez-Lopez
- Sistema de Educación Media Superior, Preparatoria 17, University of Guadalajara, Guadalajara, Mexico; 2Department of Internal Medicine, IMSS, Guadalajara, Mexico; 3Clinical Epidemiology Research Unit UMAE HECMNO, IMSS, Guadalajara, Mexico; 4Postgraduate Programmes of Public Health Sciences and Pharmacology, Guadalajara, Mexico; 5Department Molecular Microbiology II CIBO, IMSS, and University of Guadalajara, Guadalajara, Mexico; 6Clinical Epidemiology Research Unit HGZ-1, IMSS Colima, Guadalajara, Mexico
| |
Collapse
|
8
|
Baltazar-Rodriguez LM, Anaya-Ventura A, Andrade-Soto M, Monrroy-Guizar EA, Bautista-Lam JR, Jonguitud-Olguin G, Cepeda-Lopez FR, Centeno-Aguilar VA, Gonzalez-Hernandez NA, Soriano-Hernández AD, Ramirez-Flores M, Lugo-Trampe A, Rodriguez-Sanchez IP, Newton-Sanchez OA, Delgado-Enciso I. Polymorphism in the Matrix Metalloproteinase-2 Gene Promoter is Associated with Cervical Neoplasm Risk in Mexican Women. Biochem Genet 2008; 46:137-44. [DOI: 10.1007/s10528-007-9136-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2006] [Accepted: 11/14/2007] [Indexed: 11/24/2022]
|